Biogen (BIIB) stock analysis for 2026. We evaluate Leqembi's actual prescription trajectory, the Spinraza revenue decline, Skyclarys rare disease growth, diranersen Phase 2 tau data, and whether the 55% bounce from $121 to $188 is justified.
Johnson & Johnson stock analysis 2026: post-Kenvue spin-off financials, talc litigation resolution path, MedTech vs Innovative Medicine segment dynamics, dividend history, and XLV comparison.
Merck (MRK) 2026 stock outlook: Keytruda patent cliff preparation ahead of 2028 expiry, subcutaneous formulation strategy, IRA drug pricing negotiation impact, next-generation oncology pipeline depth, dividend growth sustainability, and whether MRK fits in an income or growth portfolio.